FierceBiotech Apr 22, 2026 Merck goes with Google for AI push, striking enterprise partnership worth up to $1B
FierceBiotech Apr 21, 2026 In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech Apr 17, 2026 Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans
FierceBiotech Mar 25, 2026 Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition
FierceBiotech Mar 6, 2026 Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
FierceBiotech Feb 12, 2026 Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma
FierceBiotech Feb 10, 2026 Merck teams up with British medtech to boost vaginal therapeutics delivery system
FierceBiotech Dec 19, 2025 Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners
FierceBiotech Dec 9, 2025 ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap